Tradestie Institutional Equity Comparison Engine
RADX vs QTTB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
QTTB Overall Edge
QTTB Captures Institutional Edge (4โ0 Pillars ยท 8โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Q32 Bio Inc. Common Stock (QTTB) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, RADX trades at N/M Forward P/E with -411.6% operating margin (-36.9% YoY revenue) versus QTTB at N/M Forward P/E and 34.2% operating margin (+0.0% YoY). In options structure, RADX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against QTTB sits in BREAKDOWN (42nd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
QTTB
RADX N/M vs QTTB N/M Fwd P/E
Growth & Margin Winner
QTTB
Op Margin -411.6% vs 34.2% ยท YoY -36.9% vs +0.0%
Momentum & Technical Winner
QTTB
1Y -86.0% vs +293.4% ยท 52W Pos 0% vs 30%
Options & Structure Winner
QTTB
UNCLASSIFIED (N/A IV) vs BREAKDOWN (42nd %ile IV)
RADX
NASDAQ
Radiopharm Theranostics Limited American Depositary Shares
Pharmaceutical Preparations
$0.63
-6.33% 1D
Market Cap
$10.6M
1M Return
-33.64%
1Y Return
-86.04%
Forward P/E
N/M
Unified AI Score
41.1 / 100
SELL
Tech 25.0
Fund 45.0
Flow 50.0
Mom 55.0
QTTB
NASDAQ
Q32 Bio Inc. Common Stock
Pharmaceutical Preparations
$8.34
-1.65% 1D
Market Cap
$253.8M
1M Return
-5.23%
1Y Return
+293.4%
Forward P/E
N/M
Unified AI Score
40.8 / 100
SELL
Tech 23.0
Fund 54.0
Flow 71.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
RADX -86.04%
QTTB +293.4%
Spread: +379.75 pp (QTTB Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
RADX TTM Op. Margin: -411.6%
QTTB TTM Op. Margin: 34.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RADX vs QTTB. Trailing 12-month operating profitability (RADX -411.6% vs QTTB 34.2%) and valuation multiples (RADX N/M vs QTTB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RADX | QTTB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $10.6M | $253.8M | Larger Scale | QTTB |
| Trailing P/E Ratio Valuation | N/M | 2.4x | Lower Multiple | QTTB |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -36.9% | +0.0% | Higher Growth | QTTB |
| Operating Margin (TTM) Profitability | -411.6% | 34.2% | Higher Margin | QTTB |
| Net Profit Margin Profitability | 0.0% | 60.0% | Higher Margin | QTTB |
| Return on Equity (ROE) Capital Efficiency | -174.7% | 24.0% | Higher ROE | QTTB |
| 52-Week Range Position Momentum | 0% ($1โ$16) | 30% ($2โ$24) | Stronger Trend | QTTB |
| Beta / 30D Volatility Risk Regime | 0.52ฮฒ ยท 109% Vol | 0.02ฮฒ ยท 40% Vol | Lower Realized Risk | QTTB |
| Unified Institutional Score Composite Signal | 41.1 / 100 (SELL) | 40.8 / 100 (SELL) | Higher Composite | RADX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full RADX vs QTTB Buy Guide
RADX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
QTTB
BREAKDOWN
93d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
42nd %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither RADX nor QTTB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.